<DOC>
	<DOC>NCT01120639</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy with the FDA approved chemotherapy drug temozolomide</brief_summary>
	<brief_title>PI/II of Temozolomide &amp; Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform</brief_title>
	<detailed_description>To determine the maximum tolerated dose (MTD) of hypofractionated (5 fractions) radiotherapy with temozolomide for the treatment of glioblastoma multiforme, patients will be evaluated by a multi-disciplinary team composed of radiation oncologists, neurosurgeons, and neuro-oncologists to assess for their eligibility. Patient's oncologic history, presenting symptoms, physical examination, pathology, and imaging studies will be reviewed. Patients will be evaluated for surgical candidacy and resectability. Patients who are surgical candidates will undergo a surgical resection prior to radiotherapy. Patients whose tumors are unresectable or are not good surgical candidates will undergo a biopsy for tissue diagnosis. Radiation will be delivered in five fractions.</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histopathologically confirmed newly diagnosed glioblastoma multiforme. Diagnosis must be made by surgical biopsy or excision The tumor must be supratentorial in location The planning target volume (tumor plus margin) must measure &lt;= 150 cm^3 in volume Age &gt;=18 years Life expectancy of at least 12 weeks Patient must have adequate organ function to tolerate temozolomide (details in the protocol) Patients who have previously been treated with brain irradiation to the region that would result in overlap of the radiation fields Tumor foci detected below the tentorium Multifocal disease or leptomeningeal spread Prior allergic reaction to the study drugs involved in this protocol Patients with pacemaker will be allowed to undergo CT instead of MRI Pediatric patients (age &lt;18), pregnant women, and nursing patients will be excluded</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>